<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887276</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number: 2005-000771-18</org_study_id>
    <nct_id>NCT00887276</nct_id>
  </id_info>
  <brief_title>Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia</brief_title>
  <acronym>PENCAP</acronym>
  <official_title>Prospective, Doubleblind, Randomized Multicenter Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CAPNETZ Stiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prove the clinical and bacteriological non-inferiority of
      ampicillin/amoxicillin versus moxifloxacin in hospitalized patients with non-severe
      community-acquired pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proof of the clinical non inferiority by the cure rate at the treatment of a Pneumonia at the therapy end (round 3: Day 7 to 10) with a standard penicillin in a high dosage</measure>
    <time_frame>after at least 7 days, i.e., at the time of round 3 (therapy end)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical cure rate</measure>
    <time_frame>at round 4 (follow-up: day 28 to 35)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bacteriological effectiveness on patients and seed level</measure>
    <time_frame>at round 4 (follow-up: day 28 to 35)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bacteriological sensitivity into-vitro</measure>
    <time_frame>at round 4 (follow-up: day 28 to 35)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time up to the drug-switch</measure>
    <time_frame>at round 4 (follow-up: day 28 to 35)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time until the dismissal of the patients necessity of the gift of additional antibacterial drug</measure>
    <time_frame>at round 4 (follow-up: day 28 to 35)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost reduction of the antibiotic-therapy and the complete treatment</measure>
    <time_frame>at round 4 (follow-up: day 28 to 35)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of the effectiveness by the investigator</measure>
    <time_frame>at round 4 (follow-up: day 28 to 35)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ampicillin; Amoxicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)
20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes
20 ml physiologic saline solution (placebo) (over 30 min)
20 ml physiologic saline solution (placebo) (over 30 min)
following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):
1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo
2 capsules Placebo
2 capsules Placebo
Total time of the therapy:at least 7 days, but at most 10 days</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>Avalox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin;Amoxicillin</intervention_name>
    <description>intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)
2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)
2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)
2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)
following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):
2 capsules Amoxicillin (0,5 g)
2 capsules Amoxicillin (0,5 g)
2 capsules Amoxicillin (0,5 g)
Total time of the therapy: at least 7 days, but at most 10 days</description>
    <arm_group_label>Ampicillin; Amoxicillin</arm_group_label>
    <other_name>Ampicillin Ratiopharm</other_name>
    <other_name>Amoxicillin ratiopharm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women older than 18 years with signed informed consent

          -  Women in a childbearing age with sufficient conception protection or if necessary
             negative pregnancy test

          -  Infiltrates appeared newly in the x-ray thorax

          -  Breath-conditioned chest pain

          -  At least two of the following clinical symptoms of a pneumonia:

               -  cough which is newly appeared or increasing,

               -  dyspnea

               -  mucopurulent or purulent sputum,

               -  fever (body temperature &gt;= 37.8 degrees Celsius auricalary and/or &gt;= 38,3°C
                  rectal), positive auscultation

          -  Negative legionella antigen test in the urine

          -  CRB-65-Index &lt; 3

        Exclusion Criteria:

          -  Hospitalization within the last 28 days (except for the last 72 h)

          -  Participation in another therapy study within the last 4 weeks with studies admission

          -  intake of an antibiotic longer than 24 hrs within the last 72 hours before studies
             admission

          -  Patients in the pregnancy and nursing phase

          -  Existence of contraindications opposite the examining preparations or other B-Lactam
             antibiotics or fluorochinolons

          -  Patients with a CURB-Index &gt;= 3

          -  Patients with suspicion of retrostenotic Pneumonia because of bronchial obstruction

          -  Patients with suspicion of nosocomial Pneumonia

          -  Patients with an infection by a known or suspected resistant pathogene
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Welte, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin ,Campus Virchow-Klinikum ,Medizinische Klinik : Infektiologie u. Pneumologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS-Klinikum Emil von Behring ,Lungenklinik Heckeshorn</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ruhr Universität , Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Medizinische Klinik III</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Abteilung für Pneumologie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum-Schleswig-Holstein, Campus Lübeck, Zentralklinikum, MK III, Studienzentrum Pneumologie-Infektiologie-Onkologie,</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef , Innere Abteilung</name>
      <address>
        <city>Paderborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakoniekrankenhaus Rotenburg gGmbH, Lungenklinik Unterstedt , Zentrum für Pneumologie</name>
      <address>
        <city>Rotenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm Sektion Pneumologie/Klinik für Innere Medizin II</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.capnetz.de</url>
  </link>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2014</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Reinhard Marre</name_title>
    <organization>University of Ulm</organization>
  </responsible_party>
  <keyword>Ampicillin</keyword>
  <keyword>Amoxicillin</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Community-Acquired Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

